75
Participants
Start Date
June 1, 2022
Primary Completion Date
May 1, 2026
Study Completion Date
November 1, 2026
Bumetanide Injection
Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
RECRUITING
Yale University, New Haven
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Yale University
OTHER